People · Operator
Named in public records as an officer, director or promoter · active 2012–2021 · Other Technology, Manufacturing / Industrial, Biotechnology, AI / ML, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Papa, Inc. | — | Other Technology | Series D+ | $199.2M | $2.5B | 2017 |
| Particle Industries, Inc. | — | Manufacturing / Industrial | Series B | $129.2M | $24.0M | 2017 |
| Quantopian Inc. | — | Other Technology | Series B | $49.5M | $780.7M | 2012 |
| Banyan Biomarkers, Inc. | — | Biotechnology | Series A | $23.9M | $81.9M | 2019 |
| Panorama Education, Inc. | — | AI / ML | Series A | $21.0M | $56.0M | 2015 |
| Nearpod Holdings Inc. | — | Other Technology | Series A | $13.3M | $369.5M | 2017 |
| Cloud Tiger Media, Inc. | — | Other | Series A | $12.2M | $184.4M | 2013 |
| TADA Cognitive Solutions LLC | — | Other Technology | Series A | $8.8M | $6.3M | 2018 |
| Vespr Inc. | — | Other Technology | Series A | $7.5M | $166.4M | 2013 |
| Treno, Inc. | — | Other | Seed | $6.0M | $43.4M | 2021 |
Andrew Parker at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Parker on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nabeel Hyatt | 1 | 16 |
| Nikitas Koutoupes | 1 | 14 |
| Amit Patel | 1 | 14 |
| Jim Andelman | 1 | 12 |
| THOMAS KRANE | 1 | 12 |
| Mark Jacobsen | 1 | 9 |
| Peter Segall | 1 | 8 |
| Jed Smith | 1 | 8 |
| Jennifer Carolan | 1 | 7 |
| Andrew Cleland | 1 | 7 |
| Sameer Reddy | 1 | 7 |
| Avidan Ross | 1 | 6 |
| Robert Turner | 1 | 6 |
| Tanzeen Syed | 1 | 4 |
| Fatima Husain | 1 | 4 |
| Byron Ling | 1 | 4 |
| Jackson Streeter | 1 | 4 |
| Sanjay Khosla | 1 | 3 |
| Jonathan Michael | 1 | 3 |
| James Parker | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.